How data limitations hold back AI in pharma R&D — and how organizations can reverse the trend

Most pharma teams assume AI underperforms because the models aren't advanced enough. The real blocker is the data.

AI pilots often look promising but fail to scale. Scientific information is scattered, inconsistent, and burdensome to clean. As R&D programs grow, these data gaps compound, which slows model deployment, weakens predictions, and pulls scientists into constant data triage instead of discovery.

This white paper gives readers a clear view of the data conditions needed for AI to deliver reliable results across biology, chemistry, and pharmacology. It shows how fixing the data foundation improves model accuracy, cuts out rework, and removes the friction that keeps AI from scaling.